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Various BRCA1 and BRCA2 mutation probability pre-
diction models exist which can be used to determine
equitable access to publicly funded genetic testing. In
January 2009 two of these models were introduced in
three New South Wales genetic services. From this time,
the criteria below were used to determine eligibility for
publicly funded BRCA1 and BRCA2 mutation analysis.
Individual diagnosed with breast or ovarian cancer
with one or more of the following:
￿ Combined Manchester score of 15 or higher
￿ Combined BOADICEA score of 10% or higher
￿ Synchronous or metachronous breast and ovarian
cancer
￿ Serous fallopian tube cancer
Cases not fulfilling the above criteria could be offered
testing following discussion and approval at a combined
monthly meeting of clinical staff. This was instigated
because staff thought that some clinical scenarios would
not easily fit into the BOADICEA or Manchester models
and yet should be considered for testing.
We have audited all 77 cases discussed at the meet-
ings between January 2009 and December 2010. Some
cases discussed did in fact meet the testing criteria
above. In 41 cases the decision was made to offer pub-
licly funded BRCA1 and BRCA2 mutation analysis.
Reasons cases were considered for ‘off-criteria’ testing
and bought to the meeting for discussion included:
￿ Very early age of diagnosis
￿ Pathological subtype
￿ Limited family structure
￿ Non-Western European ancestry
￿ Affected with prostate or pancreatic cancer
￿ Ashkenazi Jewish ancestry but no BRCA1 or BRCA2
founder mutation identified
We will present an analysis of the 77 cases including
case and family history, pathology, BOADICEA score,
Manchester score, outcome of discussion, and genetic
test results. We will also consider the cost-effectiveness
of ‘off-criteria’ testing.
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